|
1
|
Medici V, Rossaro L and Sturniolo GC:
Wilson disease - a practical approach to diagnosis, treatment and
follow-up. Dig Liver Dis. 39:601–609. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gow PJ, Smallwood RA, Angus PW, Smith AL,
Wall AJ and Sewell RB: Diagnosis of Wilson’s disease: an experience
over three decades. Gut. 46:415–419. 2000.
|
|
3
|
Dhawan A, Taylor RM, Cheeseman P, De Silva
P, Katsiyiannakis L and Mieli-Vergani G: Wilson’s disease in
children: 37-year experience and revised King’s score for liver
transplantation. Liver Transpl. 11:441–448. 2005.
|
|
4
|
Yuzbasiyan-Gurkan V, Brewer GJ, Abrams GD,
Main B and Giacherio D: Treatment of Wilson’s disease with zinc. V
Changes in serum levels of lipase, amylase, and alkaline
phosphatase in patients with Wilson’s disease. J Lab Clin Med.
114:520–526. 1989.
|
|
5
|
Delangle P and Mintz E: Chelation therapy
in Wilson’s disease: from penicillamine to the design of selective
bioinspired intra-cellular Cu (I) chelators. Dalton Trans.
41:6359–6370. 2012.
|
|
6
|
Merle U, Schaefer M, Ferenci P and
Stremmel W: Clinical presentation, diagnosis and long-term outcome
of Wilson’s disease: a cohort study. Gut. 56:115–120. 2007.
|
|
7
|
Walshe JM and Yealland M: Chelation
treatment of neurological Wilson’s disease. Q J Med. 86:197–204.
1993.
|
|
8
|
Taylor RM, Chen Y, Dhawan A, et al:
Triethylene tetramine dihydrochloride (trientine) in children with
Wilson disease: experience at King’s College Hospital and review of
the literature. Eur J Pediatr. 168:1061–1068. 2009.PubMed/NCBI
|
|
9
|
Brewer GJ, Askari F, Lorincz MT, et al:
Treatment of Wilson disease with ammonium tetrathiomolybdate: IV.
Comparison of tetrathiomolybdate and trientine in a double-blind
study of treatment of the neurologic presentation of Wilson
disease. Arch Neurol. 63:521–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Du SL: Clinical analysis and long-term
follow-up of 10 cases Wilson’s disease. Journal of Applied Clinical
Pediatrics. 2:85–88. 1987.(In Chinese).
|
|
11
|
Du SL, Zhang F and Cao SJ: Oral zinc salt
- a new therapy method for Wilson’s disease. Chinese Journal of
Clinical Hepatology. 1:212–213. 1985.(In Chinese).
|
|
12
|
Medici V, Trevisan CP, D’Incà R, et al:
Diagnosis and management of Wilson’s disease: results of a single
center experience. J Clin Gastroenterol. 40:936–941. 2006.
|
|
13
|
Wiggelinkhuizen M, Tilanus ME, Bollen CW
and Houwen RH: Systematic review: clinical efficacy of chelator
agents and zinc in the initial treatment of Wilson disease. Aliment
Pharmacol Ther. 29:947–958. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brewer GJ: Penicillamine should not be
used as initial therapy in Wilson’s disease. Mov Disord.
14:551–554. 1999.
|
|
15
|
Brewer GJ and Askari FK: Wilson’s disease:
clinical management and therapy. J Hepatol. 42(Suppl 1): S13–S21.
2005.
|
|
16
|
Ferenci P: Review article: diagnosis and
current therapy of Wilson’s disease. Aliment Pharmacol Ther.
19:157–165. 2004.
|
|
17
|
Linn FH, Houwen RH, van Hattum J, van der
Kleij S and van Erpecum KJ: Long-term exclusive zinc monotherapy in
symptomatic Wilson disease: experience in 17 patients. Hepatology.
50:1442–1452. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Marcellini M, Di Ciommo V, Callea F, et
al: Treatment of Wilson’s disease with zinc from the time of
diagnosis in pediatric patients: a single-hospital, 10-year
follow-up study. J Lab Clin Med. 145:139–143. 2005.
|
|
19
|
Brewer GJ, Johnson V and Kaplan J:
Treatment of Wilson’s disease with zinc: XIV. Studies of the effect
of zinc on lymphocyte function. J Lab Clin Med. 129:649–652.
1997.
|
